

**Clinical trial results:****A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer****Summary**

EudraCT number	2012-004391-19
Trial protocol	CZ GB LT HU BE ES DK DE IT NL FR PT GR
Global end of trial date	30 September 2020

**Results information**

Result version number	v1 (current)
This version publication date	30 September 2021
First version publication date	30 September 2021

**Trial information****Trial identification**

Sponsor protocol code	3475-010
-----------------------	----------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01905657
WHO universal trial number (UTN)	-
Other trial identifiers	Merck: KEYNOTE-010, Japic-CTI: 132355

Notes:

**Sponsors**

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	30 September 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 September 2015
Global end of trial reached?	Yes
Global end of trial date	30 September 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

This study compared two doses of pembrolizumab (MK-3475) versus docetaxel in participants with non-small cell lung cancer (NSCLC) who had experienced disease progression after platinum-containing systemic therapy. Participants were assigned randomly to receive either pembrolizumab 2 mg/kg once every three weeks (Q3W), pembrolizumab 10 mg/kg Q3W or docetaxel 75 mg/m<sup>2</sup> Q3W. The total number of participants randomized depended upon demonstration of sufficient objective responses at an interim analysis.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 August 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 5
Country: Number of subjects enrolled	Australia: 35
Country: Number of subjects enrolled	Belgium: 24
Country: Number of subjects enrolled	Brazil: 13
Country: Number of subjects enrolled	Canada: 19
Country: Number of subjects enrolled	Chile: 14
Country: Number of subjects enrolled	Czechia: 16
Country: Number of subjects enrolled	Denmark: 13
Country: Number of subjects enrolled	France: 107
Country: Number of subjects enrolled	Germany: 31
Country: Number of subjects enrolled	Hungary: 33
Country: Number of subjects enrolled	Italy: 25
Country: Number of subjects enrolled	Japan: 91
Country: Number of subjects enrolled	Korea, Republic of: 84
Country: Number of subjects enrolled	Lithuania: 7
Country: Number of subjects enrolled	Netherlands: 49
Country: Number of subjects enrolled	Portugal: 16

Country: Number of subjects enrolled	Russian Federation: 19
Country: Number of subjects enrolled	South Africa: 4
Country: Number of subjects enrolled	Spain: 114
Country: Number of subjects enrolled	Taiwan: 15
Country: Number of subjects enrolled	United Kingdom: 56
Country: Number of subjects enrolled	United States: 224
Country: Number of subjects enrolled	Greece: 20
Worldwide total number of subjects	1034
EEA total number of subjects	455

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	605
From 65 to 84 years	427
85 years and over	2

## Subject disposition

### Recruitment

Recruitment details:

Participants who had NSCLC and whose tumors were assessed as being programmed cell death ligand 1 (PD-L1) positive were recruited for this study.

### Pre-assignment

Screening details:

Per protocol response or progression during second and switch over pembrolizumab courses was not counted towards efficacy endpoints and adverse events during the second and switch over courses were not counted towards safety endpoints.

Final analyses for all primary and secondary endpoints was done at the protocol-specified cutoff of 30-Sep-2015.

### Period 1

Period 1 title	Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Pembrolizumab 2 mg/kg

Arm description:

Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes Q3W for up to 2 years. Qualified participants who received the first course of pembrolizumab 2 mg/kg Q3W for up to 2 years, but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q3W for up to 1 year.

Arm type	Experimental
Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	MK-3475, KEYTRUDA®
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

IV infusion

<b>Arm title</b>	Pembrolizumab 10 mg/kg
------------------	------------------------

Arm description:

Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years. Qualified participants who received the first course of pembrolizumab 10 mg/kg Q3W for up to 2 years, but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q3W for up to 1 year.

Arm type	Experimental
Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	MK-3475, KEYTRUDA®
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

IV infusion

<b>Arm title</b>	Docetaxel 75 mg/m <sup>2</sup>
------------------	--------------------------------

Arm description:

Participants received docetaxel 75 mg/m<sup>2</sup> IV over 1 hour Q3W for up to 2 years. Qualified participants

who received docetaxel 75 mg/m<sup>2</sup> Q3W for up to 2 years, but experienced disease progression, switched over to pembrolizumab, at the investigator's discretion, at 200 mg IV Q3W for up to 2 years.

Arm type	Active comparator
Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	MK-3475, KEYTRUDA®
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

IV infusion

Investigational medicinal product name	Docetaxel
Investigational medicinal product code	
Other name	TAXOTERE®
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

IV infusion

Number of subjects in period 1	Pembrolizumab 2 mg/kg	Pembrolizumab 10 mg/kg	Docetaxel 75 mg/m <sup>2</sup>
Started	345	346	343
Treated	339	343	309
Received second pembrolizumab course	14 <sup>[1]</sup>	7 <sup>[2]</sup>	0 <sup>[3]</sup>
Switched over to pembrolizumab	0 <sup>[4]</sup>	0 <sup>[5]</sup>	8 <sup>[6]</sup>
Completed	142	159	143
Not completed	203	187	200
Physician decision	5	8	12
Consent withdrawn by subject	15	21	53
Screen Failure	-	1	-
Excluded Medication	13	16	9
Adverse event, non-fatal	23	17	18
Death	40	43	47
Sponsor Decision	1	-	-
Lost to follow-up	1	2	1
Clinical Progression	103	78	59
Protocol deviation	2	1	1

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Treatment with second or crossover course of pembrolizumab was optional.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Treatment with second or crossover course of pembrolizumab was optional.

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Treatment with second or crossover course of pembrolizumab was optional.

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Treatment with second or crossover course of pembrolizumab was optional.

[5] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Treatment with second or crossover course of pembrolizumab was optional.

[6] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Treatment with second or crossover course of pembrolizumab was optional.

## Baseline characteristics

### Reporting groups

Reporting group title	Pembrolizumab 2 mg/kg
-----------------------	-----------------------

Reporting group description:

Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes Q3W for up to 2 years. Qualified participants who received the first course of pembrolizumab 2 mg/kg Q3W for up to 2 years, but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q3W for up to 1 year.

Reporting group title	Pembrolizumab 10 mg/kg
-----------------------	------------------------

Reporting group description:

Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years. Qualified participants who received the first course of pembrolizumab 10 mg/kg Q3W for up to 2 years, but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q3W for up to 1 year.

Reporting group title	Docetaxel 75 mg/m <sup>2</sup>
-----------------------	--------------------------------

Reporting group description:

Participants received docetaxel 75 mg/m<sup>2</sup> IV over 1 hour Q3W for up to 2 years. Qualified participants who received docetaxel 75 mg/m<sup>2</sup> Q3W for up to 2 years, but experienced disease progression, switched over to pembrolizumab, at the investigator's discretion, at 200 mg IV Q3W for up to 2 years.

Reporting group values	Pembrolizumab 2 mg/kg	Pembrolizumab 10 mg/kg	Docetaxel 75 mg/m <sup>2</sup>
Number of subjects	345	346	343
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	202	194	209
From 65-84 years	143	150	134
85 years and over	0	2	0
Age Continuous			
Units: Years			
arithmetic mean	62.1	62.3	61.6
standard deviation	± 9.6	± 9.7	± 9.8
Sex: Female, Male			
Units: Participants			
Female	132	133	134
Male	213	213	209
PD-L1 Tumor Expression Status			
PD-L1 expression was evaluated by immunohistochemistry (IHC) assay with a newly obtained tumor tissue with biopsy. If PD-L1 expression was observed in ≥1%, but ≤49% of tumor cells, a participant was categorized as weakly PD-L1 positive. If PD-L1 expression was observed in ≥50% of tumor cells, a participant was categorized as strongly PD-L1 positive.			
Units: Subjects			
Weakly PD-L1 Positive	206	195	191
Strongly PD-L1 Positive	139	151	152

<b>Reporting group values</b>	Total		
Number of subjects	1034		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	605		
From 65-84 years	427		
85 years and over	2		
Age Continuous			
Units: Years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male			
Units: Participants			
Female	399		
Male	635		
PD-L1 Tumor Expression Status			
PD-L1 expression was evaluated by immunohistochemistry (IHC) assay with a newly obtained tumor tissue with biopsy. If PD-L1 expression was observed in $\geq 1\%$ , but $\leq 49\%$ of tumor cells, a participant was categorized as weakly PD-L1 positive. If PD-L1 expression was observed in $\geq 50\%$ of tumor cells, a participant was categorized as strongly PD-L1 positive.			
Units: Subjects			
Weakly PD-L1 Positive	592		
Strongly PD-L1 Positive	442		



## End points

### End points reporting groups

Reporting group title	Pembrolizumab 2 mg/kg
Reporting group description: Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes Q3W for up to 2 years. Qualified participants who received the first course of pembrolizumab 2 mg/kg Q3W for up to 2 years, but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q3W for up to 1 year.	
Reporting group title	Pembrolizumab 10 mg/kg
Reporting group description: Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years. Qualified participants who received the first course of pembrolizumab 10 mg/kg Q3W for up to 2 years, but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q3W for up to 1 year.	
Reporting group title	Docetaxel 75 mg/m <sup>2</sup>
Reporting group description: Participants received docetaxel 75 mg/m <sup>2</sup> IV over 1 hour Q3W for up to 2 years. Qualified participants who received docetaxel 75 mg/m <sup>2</sup> Q3W for up to 2 years, but experienced disease progression, switched over to pembrolizumab, at the investigator's discretion, at 200 mg IV Q3W for up to 2 years.	

### Primary: Overall Survival (OS)

End point title	Overall Survival (OS)
End point description: OS was defined as the time from randomization to death due to any cause. OS was analyzed using the Kaplan-Meier method and is reported in months. Per protocol, final analysis for this primary endpoint was done for the first pembrolizumab course and docetaxel treatment arms, with a protocol-specified analysis data cutoff date of 30 September (Sep) 2015. "9999" indicates upper limit not reached, due to insufficient number of deaths in the study. Analysis population consisted of all randomized participants who had strongly PD-L1 positive and all PD-L1 positive OS data available and usable. Participants were included in the treatment group to which they were randomized.	
End point type	Primary
End point timeframe: Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)	

End point values	Pembrolizumab 2 mg/kg	Pembrolizumab 10 mg/kg	Docetaxel 75 mg/m <sup>2</sup>	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	344	346	343	
Units: Months				
median (confidence interval 95%)				
Strongly PD-L1 Positive (n=139,151,152)	14.9 (10.4 to 9999)	17.3 (11.8 to 9999)	8.2 (6.4 to 10.7)	
All PD-L1 Positive (n=344, 346, 343)	10.4 (9.4 to 11.9)	12.7 (10.0 to 17.3)	8.5 (7.5 to 9.8)	

### Statistical analyses

<b>Statistical analysis title</b>	OS Hazard Ratio
Statistical analysis description:	
Hazard Ratio based on stratified Cox regression model with treatment as a covariate and p-value based on stratified log-rank test, in accordance with the statistical analysis plan. Analysis is reported in participants with strongly PD-L1 positive tumors. Numerator=Pembrolizumab 2 mg/kg and Denominator=Docetaxel 75 mg/m <sup>2</sup> .	
Comparison groups	Pembrolizumab 2 mg/kg v Docetaxel 75 mg/m <sup>2</sup>
Number of subjects included in analysis	687
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.00024
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.54
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.38
upper limit	0.77

<b>Statistical analysis title</b>	OS Hazard Ratio
Statistical analysis description:	
Hazard Ratio based on Cox regression model with treatment as a covariate and p-value based on stratified log-rank test, in accordance with the statistical analysis plan. Analysis is reported in participants with strongly PD-L1 positive tumors. Numerator=Pembrolizumab 10 mg/kg and Denominator=Docetaxel 75 mg/m <sup>2</sup> .	
Comparison groups	Pembrolizumab 10 mg/kg v Docetaxel 75 mg/m <sup>2</sup>
Number of subjects included in analysis	689
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.00002
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.36
upper limit	0.7

<b>Statistical analysis title</b>	OS Hazard Ratio
Statistical analysis description:	
Hazard Ratio based on stratified Cox regression model with treatment as a covariate and p-value based on stratified log-rank test, in accordance with the statistical analysis plan. Analysis is reported in participants with PD-L1 positive tumors. Numerator=Pembrolizumab 2 mg/kg and Denominator=Docetaxel 75 mg/m <sup>2</sup> .	
Comparison groups	Pembrolizumab 2 mg/kg v Docetaxel 75 mg/m <sup>2</sup>

Number of subjects included in analysis	687
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.00076
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.58
upper limit	0.88

<b>Statistical analysis title</b>	OS Hazard Ratio
-----------------------------------	-----------------

Statistical analysis description:

Hazard Ratio based on stratified Cox regression model with treatment as a covariate and p-value based on stratified log-rank test, in accordance with the statistical analysis plan. Analysis is reported in participants with PD-L1 positive tumors. Numerator=Pembrolizumab 10 mg/kg and Denominator=Docetaxel 75 mg/m<sup>2</sup>.

Comparison groups	Pembrolizumab 10 mg/kg v Docetaxel 75 mg/m <sup>2</sup>
Number of subjects included in analysis	689
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.00001
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	0.75

### **Primary: Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)**

End point title	Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
-----------------	----------------------------------------------------------------------------------------------------------

End point description:

PFS was the time from the first day of study treatment to first documented progressive disease (PD) per RECIST 1.1 based on blinded independent central radiologists' review or death due to any cause, whichever occurred first. Using RECIST 1.1, PD was as either a 20% relative increase in the sum of diameters (SOD) of target lesions taking as reference the smallest sum OR an absolute increase of >5 mm in the SOD OR the appearance of new lesions. PFS was analyzed using Kaplan-Meier method and is reported in months. Per protocol final analysis for this primary endpoint was done for the first pembrolizumab course and docetaxel treatment arms, with a protocol-specified analysis data cutoff date of 30 Sep 2015. Analysis population consisted of all randomized participants who had strongly PD-L1 positive and all PD-L1 positive PFS data available and usable. Participants were included in the treatment group to which they were randomized.

End point type	Primary
----------------	---------

End point timeframe:

Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)

End point values	Pembrolizumab 2 mg/kg	Pembrolizumab 10 mg/kg	Docetaxel 75 mg/m <sup>2</sup>	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	344	346	343	
Units: Months				
median (confidence interval 95%)				
Strongly PD-L1 Positive (n=139, 151, 152)	5.2 (4.0 to 6.5)	5.2 (4.1 to 8.1)	4.1 (3.6 to 4.3)	
All PD-L1 Positive (n=344, 346, 343)	3.9 (3.1 to 4.1)	4.0 (2.6 to 4.3)	4.0 (3.1 to 4.2)	

## Statistical analyses

Statistical analysis title	PFS Hazard Ratio
Statistical analysis description: Hazard Ratio based on stratified Cox regression model with treatment as a covariate and p-value based on stratified log-rank test, in accordance with the statistical analysis plan. Analysis is reported in participants with strongly PD-L1 positive tumors. Numerator=Pembrolizumab 2 mg/kg and Denominator=Docetaxel 75 mg/m <sup>2</sup> .	
Comparison groups	Pembrolizumab 2 mg/kg v Docetaxel 75 mg/m <sup>2</sup>
Number of subjects included in analysis	687
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.00009
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.58
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.43
upper limit	0.77

Statistical analysis title	PFS Hazard Ratio
Statistical analysis description: Hazard Ratio based on stratified Cox regression model with treatment as a covariate and p-value based on stratified log-rank test, in accordance with the statistical analysis plan. Analysis is reported in participants with strongly PD-L1 positive tumors. Numerator=Pembrolizumab 10 mg/kg and Denominator=Docetaxel 75 mg/m <sup>2</sup> .	
Comparison groups	Pembrolizumab 10 mg/kg v Docetaxel 75 mg/m <sup>2</sup>

Number of subjects included in analysis	689
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.00007
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.59
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.45
upper limit	0.78

<b>Statistical analysis title</b>	PFS Hazard Ratio
-----------------------------------	------------------

Statistical analysis description:

Hazard Ratio based on stratified Cox regression model with treatment as a covariate and p-value based on stratified log-rank test, in accordance with the statistical analysis plan. Analysis is reported in participants with PD-L1 positive tumors. Numerator=Pembrolizumab 2 mg/kg and Denominator=Docetaxel 75 mg/m<sup>2</sup>.

Comparison groups	Pembrolizumab 2 mg/kg v Docetaxel 75 mg/m <sup>2</sup>
Number of subjects included in analysis	687
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.06758
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	1.04

<b>Statistical analysis title</b>	PFS Hazard Ratio
-----------------------------------	------------------

Statistical analysis description:

Hazard Ratio based on stratified Cox regression model with treatment as a covariate and p-value based on stratified log-rank test, in accordance with the statistical analysis plan. Analysis is reported in participants with PD-L1 positive tumors. Numerator=Pembrolizumab 10 mg/kg and Denominator=Docetaxel 75 mg/m<sup>2</sup>.

Comparison groups	Pembrolizumab 10 mg/kg v Docetaxel 75 mg/m <sup>2</sup>
Number of subjects included in analysis	689
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.00462
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.79

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	0.94

### Primary: Percentage of Participants Experiencing Adverse Events (AEs)

End point title	Percentage of Participants Experiencing Adverse Events (AEs) <sup>[1]</sup>
-----------------	-----------------------------------------------------------------------------

End point description:

An AE was as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily had to have a causal relationship with this treatment. An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the study drug, was also an AE. Per protocol, final analysis for this primary outcome measure was performed for the first pembrolizumab course and docetaxel treatment arms, with a protocol-specified analysis data cutoff date of 30 Sep 2015. Analysis population was the All Participants As Treated (APAT) population consisting of all participants who received  $\geq 1$  dose of study drug. Participants were included in the treatment group based on the study treatment they received.

End point type	Primary
----------------	---------

End point timeframe:

Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical comparisons between treatment arms of the current study were planned for this endpoint.

End point values	Pembrolizumab 2 mg/kg	Pembrolizumab 10 mg/kg	Docetaxel 75 mg/m <sup>2</sup>	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	339	343	309	
Units: Percentage of Participants				
number (not applicable)	97.6	96.2	96.1	

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Participants Discontinuing Study Drug Due to AEs

End point title	Percentage of Participants Discontinuing Study Drug Due to AEs <sup>[2]</sup>
-----------------	-------------------------------------------------------------------------------

End point description:

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily had to have a causal relationship with this treatment. An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the study drug, was also an AE. Per protocol final analysis for this primary endpoint was done for the first pembrolizumab course and docetaxel treatment arms, with a protocol-specified analysis data cutoff date of 30 Sep 2015. Analysis population was the APAT population consisting of all participants who got at least one dose of study drug. Participants were included in the treatment group based on the study treatment they received.

End point type	Primary
----------------	---------

End point timeframe:

Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical comparisons between treatment arms of the current study were planned for this endpoint.

End point values	Pembrolizumab 2 mg/kg	Pembrolizumab 10 mg/kg	Docetaxel 75 mg/m <sup>2</sup>	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	339	343	309	
Units: Percentage of Participants				
number (not applicable)	8.3	7.6	13.6	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Response Rate (ORR) by RECIST 1.1

End point title	Overall Response Rate (ORR) by RECIST 1.1
-----------------	-------------------------------------------

End point description:

ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR; disappearance of all target lesions) or Partial Response (PR; at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD) based on blinded independent central radiologists' review using RECIST 1.1. Per protocol, final analysis for this secondary endpoint was done for the first pembrolizumab course and docetaxel treatment arms, with a protocol-specified analysis data cutoff date of 30 Sep 2015. Analysis population consisted of all randomized participants who had strongly PD-L1 positive and all PD-L1 positive ORR data available and usable. Participants were included in the treatment group to which they were randomized.

End point type	Secondary
----------------	-----------

End point timeframe:

Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)

End point values	Pembrolizumab 2 mg/kg	Pembrolizumab 10 mg/kg	Docetaxel 75 mg/m <sup>2</sup>	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	344	346	343	
Units: Percentage of Participants				
number (confidence interval 95%)				
Strongly PD-L1 Positive (n=139, 151, 152)	30.2 (22.7 to 38.6)	29.1 (22.0 to 37.1)	7.9 (4.1 to 13.4)	
All PD-L1 Positive (n=344, 346, 343)	18.0 (14.1 to 22.5)	18.5 (14.5 to 23.0)	9.3 (6.5 to 12.9)	

## Statistical analyses

<b>Statistical analysis title</b>	ORR Difference in Percentage
Statistical analysis description:	
Analysis is reported in participants with strongly PD-L1 positive tumors. Difference in percentage is an adjusted risk difference estimated by stratified Miettinen & Nurminen method.	
Comparison groups	Pembrolizumab 2 mg/kg v Pembrolizumab 10 mg/kg
Number of subjects included in analysis	690
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.66608 <sup>[3]</sup>
Method	Miettinen & Nurminen method
Parameter estimate	Difference in Percentages
Point estimate	-2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.7
upper limit	8.2

Notes:

[3] - P-value indicated for testing a difference in percentage equal to 0 versus a difference in percentage not equal to 0, in accordance with the statistical analysis plan.

<b>Statistical analysis title</b>	ORR Difference in Percentage
Statistical analysis description:	
Analysis is reported in participants with strongly PD-L1 positive tumors. Difference in percentage is an adjusted risk difference estimated by stratified Miettinen & Nurminen method.	
Comparison groups	Pembrolizumab 10 mg/kg v Docetaxel 75 mg/m <sup>2</sup>
Number of subjects included in analysis	689
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.00001 <sup>[4]</sup>
Method	Miettinen & Nurminen method
Parameter estimate	Difference in Percentages
Point estimate	22.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	14
upper limit	30.7

Notes:

[4] - P-value indicated for testing a difference in percentage equal to 0 versus a difference in percentage greater than 0, in accordance with the statistical analysis plan.

<b>Statistical analysis title</b>	ORR Difference in Percentage
Statistical analysis description:	
Analysis is reported in participants with PD-L1 positive tumors. Difference in percentage is an adjusted risk difference estimated by stratified Miettinen & Nurminen method.	
Comparison groups	Pembrolizumab 2 mg/kg v Docetaxel 75 mg/m <sup>2</sup>



Number of subjects included in analysis	687
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.00045 <sup>[5]</sup>
Method	Miettinen & Nurminen method
Parameter estimate	Difference in Percentages
Point estimate	8.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.6
upper limit	13.9

Notes:

[5] - P-value indicated for testing a difference in percentage equal to 0 versus a difference in percentage greater than 0, in accordance with the statistical analysis plan.

<b>Statistical analysis title</b>	ORR Difference in Percentage
-----------------------------------	------------------------------

Statistical analysis description:

Analysis is reported in participants with PD-L1 positive tumors. Difference in percentage is an adjusted risk difference estimated by stratified Miettinen & Nurminen method.

Comparison groups	Pembrolizumab 10 mg/kg v Docetaxel 75 mg/m <sup>2</sup>
Number of subjects included in analysis	689
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.00024 <sup>[6]</sup>
Method	Miettinen & Nurminen method
Parameter estimate	Difference in Percentages
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.1
upper limit	14.3

Notes:

[6] - P-value indicated for testing a difference in percentage equal to 0 versus a difference in percentage greater than 0, in accordance with the statistical analysis plan.

### **Secondary: Duration of Response (DOR) by RECIST 1.1**

End point title	Duration of Response (DOR) by RECIST 1.1
-----------------	------------------------------------------

End point description:

DOR is measured from the time criteria were first met for CR/PR (whichever occurred first) until the first date that death or PD was objectively documented. Non-responders weren't included in the analysis. DOR was analyzed using the Kaplan-Meier method and is reported in weeks. Per protocol final analysis for this secondary endpoint was done for the first pembrolizumab course and docetaxel treatment arms with a protocol-specified analysis data cutoff date of 30 Sep 2015. "9999" indicates median and upper limit not reached, no progressive disease by the time of last disease assessment. Analysis population consisted of all randomized participants who demonstrated a CR/PR and had strongly PD-L1 positive and all PD-L1 positive DOR data available and usable. Participants were included in the treatment group to which they were randomized.

End point type	Secondary
----------------	-----------

End point timeframe:

Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)

<b>End point values</b>	Pembrolizumab 2 mg/kg	Pembrolizumab 10 mg/kg	Docetaxel 75 mg/m <sup>2</sup>	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	62	64	32	
Units: Weeks				
median (full range (min-max))				
Strongly PD-L1 Positive (n=42, 44, 12)	9999 (3 to 9999)	9999 (9 to 9999)	35 (9 to 9999)	
All PD-L1 Positive (n=62, 64, 32)	9999 (3 to 9999)	9999 (9 to 9999)	27 (6 to 9999)	

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Safety: Up to ~35 months for pembrolizumab first course and up to additional ~27 months for pembrolizumab second and switch over courses; Deaths: Up to ~83 months for pembrolizumab first, second and switch over courses

Adverse event reporting additional description:

Safety, deaths were analyzed by treatment (pembrolizumab, docetaxel), course (1st, 2nd, switch over).

Deaths: all randomized participants; safety: Participants who got  $\geq 1$  dose of study drug.

Disease progression (DP) wasn't an AE unless drug-related; MedDRA terms "Neoplasm progression (NP)", "Malignant NP", "DP" unrelated to study drug are excluded

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.0
--------------------	------

### Reporting groups

Reporting group title	Pembrolizumab 2 mg/kg First Course
-----------------------	------------------------------------

Reporting group description:

Participants received pembrolizumab 2 mg/kg IV over 30 minutes Q3W for up to 2 years.

Reporting group title	Pembrolizumab 10 mg/kg First Course
-----------------------	-------------------------------------

Reporting group description:

Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.

Reporting group title	Docetaxel 75 mg/m <sup>2</sup>
-----------------------	--------------------------------

Reporting group description:

Participants received docetaxel 75 mg/m<sup>2</sup> IV over 1 hour Q3W for up to 2 years.

Reporting group title	Pembrolizumab 2 mg/kg First Course to Second Course
-----------------------	-----------------------------------------------------

Reporting group description:

Qualified participants who received the first course of pembrolizumab 2 mg/kg Q3W for up to 2 years, but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q3W for up to 1 year.

Reporting group title	Pembrolizumab 10 mg/kg First Course to Second Course
-----------------------	------------------------------------------------------

Reporting group description:

Qualified participants who received the first course of pembrolizumab 10 mg/kg Q3W for up to 2 years, but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q3W for up to 1 year.

Reporting group title	Docetaxel 75 mg/m <sup>2</sup> to Switched Over to Pembrolizumab
-----------------------	------------------------------------------------------------------

Reporting group description:

Qualified participants who received docetaxel 75 mg/m<sup>2</sup> Q3W for up to 2 years, but experienced disease progression, switched over to pembrolizumab, at the investigator's discretion, at 200 mg IV Q3W for up to 2 years.

Serious adverse events	Pembrolizumab 2 mg/kg First Course	Pembrolizumab 10 mg/kg First Course	Docetaxel 75 mg/m <sup>2</sup>
Total subjects affected by serious adverse events			
subjects affected / exposed	124 / 339 (36.58%)	133 / 343 (38.78%)	107 / 309 (34.63%)
number of deaths (all causes)	294	289	303
number of deaths resulting from adverse events	2	3	5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Basal cell carcinoma			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial carcinoma			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cancer pain			
subjects affected / exposed	0 / 339 (0.00%)	2 / 343 (0.58%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric cancer			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Malignant pleural effusion			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to central nervous system			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraneoplastic syndrome			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour associated fever			

subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Hypertension			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 339 (0.00%)	2 / 343 (0.58%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 2	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery occlusion			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava occlusion			

subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	2 / 339 (0.59%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Axillary pain			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	2 / 339 (0.59%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	3 / 339 (0.88%)	3 / 343 (0.87%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 3	0 / 3	0 / 1
Fatigue			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	3 / 339 (0.88%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			

subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Oedema			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	2 / 339 (0.59%)	1 / 343 (0.29%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	3 / 339 (0.88%)	4 / 343 (1.17%)	4 / 309 (1.29%)
occurrences causally related to treatment / all	1 / 3	1 / 4	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug hypersensitivity			

subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Erectile dysfunction			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Aspiration			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Bronchial haemorrhage			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	6 / 339 (1.77%)	1 / 343 (0.29%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	1 / 6	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	6 / 339 (1.77%)	2 / 343 (0.58%)	6 / 309 (1.94%)
occurrences causally related to treatment / all	1 / 6	1 / 2	3 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	3 / 339 (0.88%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hypoxia			



subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Painful respiration			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	3 / 339 (0.88%)	4 / 343 (1.17%)	3 / 309 (0.97%)
occurrences causally related to treatment / all	2 / 3	0 / 5	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	1 / 339 (0.29%)	2 / 343 (0.58%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 2	1 / 1
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Pneumonitis			
subjects affected / exposed	14 / 339 (4.13%)	10 / 343 (2.92%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	13 / 15	9 / 10	2 / 2
deaths causally related to treatment / all	2 / 2	1 / 1	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	3 / 309 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			

subjects affected / exposed	8 / 339 (2.36%)	8 / 343 (2.33%)	5 / 309 (1.62%)
occurrences causally related to treatment / all	0 / 8	0 / 8	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Pulmonary haemorrhage			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	1 / 339 (0.29%)	2 / 343 (0.58%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pulmonary vascular disorder			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Respiratory failure			
subjects affected / exposed	2 / 339 (0.59%)	1 / 343 (0.29%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Completed suicide			

subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Confusional state			
subjects affected / exposed	3 / 339 (0.88%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	1 / 4	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disorientation			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device dislocation			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase			

increased			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
C-reactive protein increased			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			

Contusion			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia, obstructive			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury			

subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Lumbar vertebral fracture			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiation pneumonitis			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seroma			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracic vertebral fracture			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic intracranial haemorrhage			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	2 / 339 (0.59%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Pyloric stenosis			

subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheo-oesophageal fistula			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriosclerosis coronary artery			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	3 / 339 (0.88%)	1 / 343 (0.29%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	1 / 4	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial thrombosis			

subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block complete			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 339 (0.00%)	2 / 343 (0.58%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Cardiac failure			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiac failure acute			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Cardiac tamponade			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardio-respiratory arrest			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardiomyopathy			



subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Pericardial effusion			
subjects affected / exposed	3 / 339 (0.88%)	2 / 343 (0.58%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 3	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Restrictive cardiomyopathy			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			

subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brain oedema			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cerebral ischaemia			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Cognitive disorder			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiparesis			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			

subjects affected / exposed	1 / 339 (0.29%)	2 / 343 (0.58%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Myelitis transverse			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurological decompensation			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 339 (0.00%)	2 / 343 (0.58%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic leukoencephalopathy			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorder			

subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	3 / 339 (0.88%)	4 / 343 (1.17%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
<b>Bone marrow failure</b>			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Eosinophilia</b>			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Febrile neutropenia</b>			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	11 / 309 (3.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1	10 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
<b>Leukopenia</b>			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Lymph node pain</b>			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Microcytic anaemia</b>			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Neutropenia</b>			

subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	5 / 309 (1.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	4 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Normocytic anaemia			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 339 (0.59%)	1 / 343 (0.29%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain lower			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune pancreatitis			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	3 / 339 (0.88%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	3 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ischaemic			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			

subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 339 (0.29%)	2 / 343 (0.58%)	3 / 309 (0.97%)
occurrences causally related to treatment / all	0 / 1	2 / 2	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 339 (0.00%)	2 / 343 (0.58%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	2 / 339 (0.59%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			

subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intra-abdominal haemorrhage			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	2 / 339 (0.59%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal hypomotility			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal obstruction			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal stenosis			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	2 / 339 (0.59%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			

subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 1	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Autoimmune hepatitis			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	2 / 339 (0.59%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice cholestatic			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary colic			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Drug eruption			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			



subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	2 / 339 (0.59%)	2 / 343 (0.58%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 2	0 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder hypertrophy			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tubulointerstitial nephritis			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary bladder polyp			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	2 / 339 (0.59%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			

Adrenal insufficiency			
subjects affected / exposed	0 / 339 (0.00%)	2 / 343 (0.58%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adrenal suppression			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthyroidism			
subjects affected / exposed	0 / 339 (0.00%)	2 / 343 (0.58%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophysitis			
subjects affected / exposed	0 / 339 (0.00%)	2 / 343 (0.58%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypopituitarism			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypothyroidism			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Arthritis			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	3 / 339 (0.88%)	2 / 343 (0.58%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 3	0 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bursitis			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle fatigue			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle haemorrhage			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle necrosis			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			

subjects affected / exposed	2 / 339 (0.59%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myopathy			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoporosis			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoporotic fracture			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal stenosis			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovitis			

subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tendonitis</b>			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tenosynovitis</b>			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
<b>Bronchitis</b>			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	3 / 309 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cellulitis</b>			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Clostridium difficile infection</b>			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Device related sepsis</b>			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Diverticulitis</b>			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Endocarditis</b>			

subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
External ear cellulitis			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious pleural effusion			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine infection			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			

subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal infection			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngitis			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phlebitis infective			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural infection			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	1 / 1	0 / 0
Pneumonia			

subjects affected / exposed	20 / 339 (5.90%)	21 / 343 (6.12%)	19 / 309 (6.15%)
occurrences causally related to treatment / all	3 / 22	2 / 22	6 / 22
deaths causally related to treatment / all	0 / 4	0 / 4	0 / 2
Pneumonia bacterial			
subjects affected / exposed	1 / 339 (0.29%)	2 / 343 (0.58%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia haemophilus			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyopneumothorax			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	4 / 339 (1.18%)	3 / 343 (0.87%)	3 / 309 (0.97%)
occurrences causally related to treatment / all	0 / 4	0 / 3	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Respiratory tract infection viral			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			



subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	3 / 309 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular device infection			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound sepsis			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective spondylitis			

subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis externa			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	3 / 309 (0.97%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	1 / 339 (0.29%)	2 / 343 (0.58%)	4 / 309 (1.29%)
occurrences causally related to treatment / all	0 / 1	0 / 2	3 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Diabetes mellitus			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	1 / 339 (0.29%)	5 / 343 (1.46%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoalbuminaemia			

subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hypoglycaemia</b>			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hypokalaemia</b>			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hyponatraemia</b>			
subjects affected / exposed	1 / 339 (0.29%)	2 / 343 (0.58%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 1	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hypophosphataemia</b>			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Type 1 diabetes mellitus</b>			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Pembrolizumab 2 mg/kg First Course to Second Course	Pembrolizumab 10 mg/kg First Course to Second Course	Docetaxel 75 mg/m <sup>2</sup> to Switched Over to Pembrolizumab
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	5 / 14 (35.71%)	2 / 7 (28.57%)	1 / 8 (12.50%)
number of deaths (all causes)	4	2	6
number of deaths resulting from adverse events	0	0	0
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
Basal cell carcinoma			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial carcinoma			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cancer pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric cancer			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant pleural effusion			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to central nervous system			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraneoplastic syndrome			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour associated fever			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery occlusion			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava occlusion			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Axillary pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug hypersensitivity			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Erectile dysfunction			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Aspiration			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			



subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Painful respiration			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			

subjects affected / exposed	2 / 14 (14.29%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary vascular disorder			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Completed suicide			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disorientation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device dislocation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase			

increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
C-reactive protein increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			

Contusion			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia, obstructive			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiation pneumonitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seroma			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracic vertebral fracture			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic intracranial haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Pyloric stenosis			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheo-oesophageal fistula			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriosclerosis coronary artery			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial thrombosis			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block complete			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiac failure acute			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac tamponade			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardio-respiratory arrest			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiomyopathy			



subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Restrictive cardiomyopathy			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brain oedema			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral ischaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cognitive disorder			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiparesis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelitis transverse			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurological decompensation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic leukoencephalopathy			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorder			

subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bone marrow failure</b>			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Eosinophilia</b>			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Febrile neutropenia</b>			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Leukopenia</b>			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Lymph node pain</b>			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Microcytic anaemia</b>			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Neutropenia</b>			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Normocytic anaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain lower			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune pancreatitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ischaemic			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intra-abdominal haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal hypomotility			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal obstruction			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal stenosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Autoimmune hepatitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice cholestatic			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary colic			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Drug eruption			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			



subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder hypertrophy			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary bladder polyp			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			

Adrenal insufficiency			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adrenal suppression			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthyroidism			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophysitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypopituitarism			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypothyroidism			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Arthritis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bursitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle fatigue			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle necrosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myopathy			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoporosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoporotic fracture			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal stenosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovitis			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tendonitis</b>			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tenosynovitis</b>			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
<b>Bronchitis</b>			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cellulitis</b>			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Clostridium difficile infection</b>			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Device related sepsis</b>			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Diverticulitis</b>			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Endocarditis</b>			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
External ear cellulitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious pleural effusion			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phlebitis infective			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia haemophilus			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyopneumothorax			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			



subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular device infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound sepsis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective spondylitis			

subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis externa			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoalbuminaemia			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophosphataemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 1 diabetes mellitus			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Pembrolizumab 2 mg/kg First Course	Pembrolizumab 10 mg/kg First Course	Docetaxel 75 mg/m <sup>2</sup>
Total subjects affected by non-serious adverse events			
subjects affected / exposed	312 / 339 (92.04%)	301 / 343 (87.76%)	279 / 309 (90.29%)
Vascular disorders			
Embolism			
subjects affected / exposed	2 / 339 (0.59%)	1 / 343 (0.29%)	1 / 309 (0.32%)
occurrences (all)	2	1	1
Hypertension			

subjects affected / exposed	15 / 339 (4.42%)	12 / 343 (3.50%)	6 / 309 (1.94%)
occurrences (all)	16	12	7
Orthostatic hypotension			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	2 / 309 (0.65%)
occurrences (all)	1	1	3
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	44 / 339 (12.98%)	45 / 343 (13.12%)	51 / 309 (16.50%)
occurrences (all)	60	59	72
Chest pain			
subjects affected / exposed	25 / 339 (7.37%)	32 / 343 (9.33%)	22 / 309 (7.12%)
occurrences (all)	26	40	23
Fatigue			
subjects affected / exposed	102 / 339 (30.09%)	88 / 343 (25.66%)	106 / 309 (34.30%)
occurrences (all)	122	107	131
Oedema peripheral			
subjects affected / exposed	30 / 339 (8.85%)	28 / 343 (8.16%)	34 / 309 (11.00%)
occurrences (all)	35	30	37
Pyrexia			
subjects affected / exposed	51 / 339 (15.04%)	40 / 343 (11.66%)	42 / 309 (13.59%)
occurrences (all)	68	64	56
Gait disturbance			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	4 / 309 (1.29%)
occurrences (all)	1	1	4
Influenza like illness			
subjects affected / exposed	9 / 339 (2.65%)	12 / 343 (3.50%)	3 / 309 (0.97%)
occurrences (all)	15	16	6
Infusion site extravasation			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	4 / 309 (1.29%)
occurrences (all)	0	1	4
Injection site haemorrhage			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Oedema			

subjects affected / exposed occurrences (all)	7 / 339 (2.06%) 9	3 / 343 (0.87%) 3	6 / 309 (1.94%) 6
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	82 / 339 (24.19%)	75 / 343 (21.87%)	43 / 309 (13.92%)
occurrences (all)	104	94	47
Dyspnoea			
subjects affected / exposed	81 / 339 (23.89%)	79 / 343 (23.03%)	65 / 309 (21.04%)
occurrences (all)	92	95	71
Haemoptysis			
subjects affected / exposed	26 / 339 (7.67%)	26 / 343 (7.58%)	20 / 309 (6.47%)
occurrences (all)	37	33	29
Productive cough			
subjects affected / exposed	21 / 339 (6.19%)	30 / 343 (8.75%)	10 / 309 (3.24%)
occurrences (all)	30	32	12
Chronic obstructive pulmonary disease			
subjects affected / exposed	3 / 339 (0.88%)	8 / 343 (2.33%)	1 / 309 (0.32%)
occurrences (all)	4	8	1
Dysphonia			
subjects affected / exposed	13 / 339 (3.83%)	8 / 343 (2.33%)	9 / 309 (2.91%)
occurrences (all)	14	9	9
Oropharyngeal pain			
subjects affected / exposed	9 / 339 (2.65%)	12 / 343 (3.50%)	7 / 309 (2.27%)
occurrences (all)	11	12	7
Pneumonitis			
subjects affected / exposed	8 / 339 (2.36%)	7 / 343 (2.04%)	1 / 309 (0.32%)
occurrences (all)	9	8	1
Pulmonary haemorrhage			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	1
Sputum discoloured			
subjects affected / exposed	2 / 339 (0.59%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences (all)	2	1	0
Psychiatric disorders			

Anxiety			
subjects affected / exposed	18 / 339 (5.31%)	16 / 343 (4.66%)	9 / 309 (2.91%)
occurrences (all)	19	16	9
Insomnia			
subjects affected / exposed	27 / 339 (7.96%)	22 / 343 (6.41%)	22 / 309 (7.12%)
occurrences (all)	29	22	24
Depressed mood			
subjects affected / exposed	0 / 339 (0.00%)	3 / 343 (0.87%)	1 / 309 (0.32%)
occurrences (all)	0	4	1
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	26 / 339 (7.67%)	20 / 343 (5.83%)	5 / 309 (1.62%)
occurrences (all)	35	22	6
Aspartate aminotransferase increased			
subjects affected / exposed	20 / 339 (5.90%)	21 / 343 (6.12%)	4 / 309 (1.29%)
occurrences (all)	29	24	4
Blood alkaline phosphatase increased			
subjects affected / exposed	12 / 339 (3.54%)	19 / 343 (5.54%)	5 / 309 (1.62%)
occurrences (all)	16	19	5
Blood creatinine increased			
subjects affected / exposed	19 / 339 (5.60%)	17 / 343 (4.96%)	4 / 309 (1.29%)
occurrences (all)	26	20	4
Neutrophil count decreased			
subjects affected / exposed	3 / 339 (0.88%)	3 / 343 (0.87%)	25 / 309 (8.09%)
occurrences (all)	4	4	45
Weight decreased			
subjects affected / exposed	32 / 339 (9.44%)	33 / 343 (9.62%)	11 / 309 (3.56%)
occurrences (all)	37	34	13
White blood cell count decreased			
subjects affected / exposed	0 / 339 (0.00%)	3 / 343 (0.87%)	17 / 309 (5.50%)
occurrences (all)	0	6	29
Amylase increased			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences (all)	0	2	0
Blood thyroid stimulating hormone increased			

subjects affected / exposed occurrences (all)	5 / 339 (1.47%) 5	4 / 343 (1.17%) 6	0 / 309 (0.00%) 0
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	15 / 339 (4.42%) 20	5 / 343 (1.46%) 5	3 / 309 (0.97%) 4
Serum ferritin decreased subjects affected / exposed occurrences (all)	1 / 339 (0.29%) 1	0 / 343 (0.00%) 0	0 / 309 (0.00%) 0
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	4 / 339 (1.18%) 4	5 / 343 (1.46%) 6	2 / 309 (0.65%) 3
Fall subjects affected / exposed occurrences (all)	4 / 339 (1.18%) 5	3 / 343 (0.87%) 3	3 / 309 (0.97%) 3
Joint dislocation subjects affected / exposed occurrences (all)	0 / 339 (0.00%) 0	0 / 343 (0.00%) 0	0 / 309 (0.00%) 0
Skin laceration subjects affected / exposed occurrences (all)	0 / 339 (0.00%) 0	0 / 343 (0.00%) 0	0 / 309 (0.00%) 0
Tendon injury subjects affected / exposed occurrences (all)	0 / 339 (0.00%) 0	0 / 343 (0.00%) 0	0 / 309 (0.00%) 0
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	30 / 339 (8.85%) 37	24 / 343 (7.00%) 26	12 / 309 (3.88%) 15
Dysgeusia subjects affected / exposed occurrences (all)	5 / 339 (1.47%) 5	8 / 343 (2.33%) 8	19 / 309 (6.15%) 24
Neuropathy peripheral subjects affected / exposed occurrences (all)	8 / 339 (2.36%) 9	9 / 343 (2.62%) 9	37 / 309 (11.97%) 39
Headache			

subjects affected / exposed	42 / 339 (12.39%)	35 / 343 (10.20%)	22 / 309 (7.12%)
occurrences (all)	47	43	25
Paraesthesia			
subjects affected / exposed	7 / 339 (2.06%)	8 / 343 (2.33%)	20 / 309 (6.47%)
occurrences (all)	9	9	22
Peripheral sensory neuropathy			
subjects affected / exposed	5 / 339 (1.47%)	6 / 343 (1.75%)	17 / 309 (5.50%)
occurrences (all)	7	6	17
Balance disorder			
subjects affected / exposed	3 / 339 (0.88%)	1 / 343 (0.29%)	1 / 309 (0.32%)
occurrences (all)	3	2	1
Cerebral ischaemia			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Dysarthria			
subjects affected / exposed	0 / 339 (0.00%)	1 / 343 (0.29%)	4 / 309 (1.29%)
occurrences (all)	0	1	4
Facial paralysis			
subjects affected / exposed	2 / 339 (0.59%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences (all)	2	0	0
Sciatica			
subjects affected / exposed	4 / 339 (1.18%)	2 / 343 (0.58%)	1 / 309 (0.32%)
occurrences (all)	5	2	1
Amnesia			
subjects affected / exposed	1 / 339 (0.29%)	1 / 343 (0.29%)	0 / 309 (0.00%)
occurrences (all)	1	1	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	37 / 339 (10.91%)	32 / 343 (9.33%)	61 / 309 (19.74%)
occurrences (all)	50	43	71
Neutropenia			
subjects affected / exposed	1 / 339 (0.29%)	2 / 343 (0.58%)	47 / 309 (15.21%)
occurrences (all)	1	3	103
Iron deficiency anaemia			
subjects affected / exposed	1 / 339 (0.29%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences (all)	1	0	0



Thrombocytopenia subjects affected / exposed occurrences (all)	4 / 339 (1.18%) 4	6 / 343 (1.75%) 6	7 / 309 (2.27%) 7
Eye disorders			
Lacrimation increased subjects affected / exposed occurrences (all)	2 / 339 (0.59%) 2	2 / 343 (0.58%) 3	17 / 309 (5.50%) 18
Conjunctival haemorrhage subjects affected / exposed occurrences (all)	2 / 339 (0.59%) 2	0 / 343 (0.00%) 0	0 / 309 (0.00%) 0
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	20 / 339 (5.90%) 24	21 / 343 (6.12%) 23	13 / 309 (4.21%) 17
Constipation subjects affected / exposed occurrences (all)	59 / 339 (17.40%) 65	57 / 343 (16.62%) 64	41 / 309 (13.27%) 47
Diarrhoea subjects affected / exposed occurrences (all)	62 / 339 (18.29%) 91	51 / 343 (14.87%) 62	81 / 309 (26.21%) 111
Nausea subjects affected / exposed occurrences (all)	87 / 339 (25.66%) 105	75 / 343 (21.87%) 92	65 / 309 (21.04%) 80
Stomatitis subjects affected / exposed occurrences (all)	19 / 339 (5.60%) 22	13 / 343 (3.79%) 15	49 / 309 (15.86%) 72
Vomiting subjects affected / exposed occurrences (all)	51 / 339 (15.04%) 60	48 / 343 (13.99%) 59	32 / 309 (10.36%) 37
Abdominal pain upper subjects affected / exposed occurrences (all)	11 / 339 (3.24%) 11	12 / 343 (3.50%) 13	7 / 309 (2.27%) 7
Dyspepsia subjects affected / exposed occurrences (all)	10 / 339 (2.95%) 13	5 / 343 (1.46%) 6	14 / 309 (4.53%) 14
Oral pain			

subjects affected / exposed occurrences (all)	2 / 339 (0.59%) 3	0 / 343 (0.00%) 0	6 / 309 (1.94%) 6
Salivary hypersecretion subjects affected / exposed occurrences (all)	0 / 339 (0.00%) 0	1 / 343 (0.29%) 1	0 / 309 (0.00%) 0
Skin and subcutaneous tissue disorders			
Alopecia subjects affected / exposed occurrences (all)	6 / 339 (1.77%) 6	5 / 343 (1.46%) 5	110 / 309 (35.60%) 112
Dry skin subjects affected / exposed occurrences (all)	15 / 339 (4.42%) 19	19 / 343 (5.54%) 25	8 / 309 (2.59%) 8
Pruritus subjects affected / exposed occurrences (all)	45 / 339 (13.27%) 62	52 / 343 (15.16%) 76	11 / 309 (3.56%) 11
Rash subjects affected / exposed occurrences (all)	48 / 339 (14.16%) 62	59 / 343 (17.20%) 78	22 / 309 (7.12%) 22
Erythema subjects affected / exposed occurrences (all)	3 / 339 (0.88%) 3	7 / 343 (2.04%) 7	5 / 309 (1.62%) 5
Macule subjects affected / exposed occurrences (all)	0 / 339 (0.00%) 0	2 / 343 (0.58%) 2	0 / 309 (0.00%) 0
Skin exfoliation subjects affected / exposed occurrences (all)	2 / 339 (0.59%) 2	0 / 343 (0.00%) 0	2 / 309 (0.65%) 2
Skin lesion subjects affected / exposed occurrences (all)	4 / 339 (1.18%) 4	3 / 343 (0.87%) 3	1 / 309 (0.32%) 2
Renal and urinary disorders			
Renal failure subjects affected / exposed occurrences (all)	4 / 339 (1.18%) 4	1 / 343 (0.29%) 1	0 / 309 (0.00%) 0
Endocrine disorders			

Hyperthyroidism subjects affected / exposed occurrences (all)	12 / 339 (3.54%) 13	19 / 343 (5.54%) 19	3 / 309 (0.97%) 3
Hypothyroidism subjects affected / exposed occurrences (all)	29 / 339 (8.55%) 30	29 / 343 (8.45%) 34	1 / 309 (0.32%) 1
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	48 / 339 (14.16%) 67	42 / 343 (12.24%) 50	29 / 309 (9.39%) 34
Back pain subjects affected / exposed occurrences (all)	41 / 339 (12.09%) 48	45 / 343 (13.12%) 51	23 / 309 (7.44%) 25
Musculoskeletal pain subjects affected / exposed occurrences (all)	39 / 339 (11.50%) 48	37 / 343 (10.79%) 41	10 / 309 (3.24%) 16
Myalgia subjects affected / exposed occurrences (all)	20 / 339 (5.90%) 28	15 / 343 (4.37%) 18	35 / 309 (11.33%) 52
Pain in extremity subjects affected / exposed occurrences (all)	22 / 339 (6.49%) 23	26 / 343 (7.58%) 27	13 / 309 (4.21%) 16
Flank pain subjects affected / exposed occurrences (all)	3 / 339 (0.88%) 3	1 / 343 (0.29%) 1	2 / 309 (0.65%) 2
Spondylolisthesis subjects affected / exposed occurrences (all)	0 / 339 (0.00%) 0	0 / 343 (0.00%) 0	0 / 309 (0.00%) 0
Infections and infestations			
Nasopharyngitis subjects affected / exposed occurrences (all)	20 / 339 (5.90%) 26	23 / 343 (6.71%) 29	16 / 309 (5.18%) 16
Upper respiratory tract infection subjects affected / exposed occurrences (all)	18 / 339 (5.31%) 19	18 / 343 (5.25%) 26	11 / 309 (3.56%) 12
Urinary tract infection			

subjects affected / exposed	19 / 339 (5.60%)	10 / 343 (2.92%)	9 / 309 (2.91%)
occurrences (all)	21	12	10
Cystitis			
subjects affected / exposed	5 / 339 (1.47%)	2 / 343 (0.58%)	0 / 309 (0.00%)
occurrences (all)	5	2	0
Fungal infection			
subjects affected / exposed	3 / 339 (0.88%)	2 / 343 (0.58%)	2 / 309 (0.65%)
occurrences (all)	5	2	2
Influenza			
subjects affected / exposed	8 / 339 (2.36%)	3 / 343 (0.87%)	3 / 309 (0.97%)
occurrences (all)	8	3	3
Liver abscess			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Paraspinal abscess			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	14 / 339 (4.13%)	7 / 343 (2.04%)	9 / 309 (2.91%)
occurrences (all)	16	12	10
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	104 / 339 (30.68%)	80 / 343 (23.32%)	74 / 309 (23.95%)
occurrences (all)	123	93	87
Hyperglycaemia			
subjects affected / exposed	18 / 339 (5.31%)	15 / 343 (4.37%)	12 / 309 (3.88%)
occurrences (all)	27	27	13
Folate deficiency			
subjects affected / exposed	0 / 339 (0.00%)	0 / 343 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	6 / 339 (1.77%)	7 / 343 (2.04%)	1 / 309 (0.32%)
occurrences (all)	7	8	1
Hypertriglyceridaemia			
subjects affected / exposed	10 / 339 (2.95%)	10 / 343 (2.92%)	3 / 309 (0.97%)
occurrences (all)	14	15	4

Hypokalaemia			
subjects affected / exposed	15 / 339 (4.42%)	8 / 343 (2.33%)	11 / 309 (3.56%)
occurrences (all)	18	16	12

<b>Non-serious adverse events</b>	Pembrolizumab 2 mg/kg First Course to Second Course	Pembrolizumab 10 mg/kg First Course to Second Course	Docetaxel 75 mg/m <sup>2</sup> to Switched Over to Pembrolizumab
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 14 (64.29%)	5 / 7 (71.43%)	7 / 8 (87.50%)
Vascular disorders			
Embolism			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Hypertension			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	3
Orthostatic hypotension			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 14 (0.00%)	2 / 7 (28.57%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
Chest pain			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Fatigue			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Oedema peripheral			
subjects affected / exposed	1 / 14 (7.14%)	1 / 7 (14.29%)	1 / 8 (12.50%)
occurrences (all)	1	1	1
Pyrexia			
subjects affected / exposed	2 / 14 (14.29%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Gait disturbance			

subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Influenza like illness			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Infusion site extravasation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Injection site haemorrhage			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Oedema			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 14 (14.29%)	0 / 7 (0.00%)	1 / 8 (12.50%)
occurrences (all)	2	0	1
Dyspnoea			
subjects affected / exposed	2 / 14 (14.29%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	2	1	0
Haemoptysis			
subjects affected / exposed	1 / 14 (7.14%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
Productive cough			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Dysphonia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Oropharyngeal pain			

subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1
Pneumonitis subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Pulmonary haemorrhage subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Sputum discoloured subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 7 (14.29%) 2	0 / 8 (0.00%) 0
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1
Depressed mood subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 2	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 2	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 2	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Blood creatinine increased subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Neutrophil count decreased			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Amylase increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Blood thyroid stimulating hormone increased			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Serum ferritin decreased			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Fall			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Joint dislocation			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Skin laceration			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Tendon injury			



subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Dysgeusia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Paraesthesia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Cerebral ischaemia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Dysarthria			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Facial paralysis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Sciatica			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0

Amnesia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	2 / 14 (14.29%) 3	0 / 7 (0.00%) 0	1 / 8 (12.50%) 2
Neutropenia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1
Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0
Eye disorders			
Lacrimation increased subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Conjunctival haemorrhage subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	2 / 14 (14.29%) 2	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1
Constipation subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 2	1 / 7 (14.29%) 1	1 / 8 (12.50%) 1
Diarrhoea subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 2	1 / 7 (14.29%) 1	2 / 8 (25.00%) 5
Nausea subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1
Stomatitis			

subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Abdominal pain upper			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Dyspepsia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Oral pain			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Salivary hypersecretion			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	1 / 14 (7.14%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	4 / 14 (28.57%)	0 / 7 (0.00%)	1 / 8 (12.50%)
occurrences (all)	4	0	1
Rash			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Erythema			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Macule			
subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1

Skin exfoliation subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Skin lesion subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Renal and urinary disorders Renal failure subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1
Endocrine disorders Hyperthyroidism subjects affected / exposed occurrences (all)	2 / 14 (14.29%) 2	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Hypothyroidism subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	2 / 7 (28.57%) 3	0 / 8 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 2	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0
Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 7 (0.00%) 0	1 / 8 (12.50%) 2
Pain in extremity subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Flank pain subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1

Spondylolisthesis subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Infections and infestations			
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 7 (14.29%) 1	1 / 8 (12.50%) 1
Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 2	2 / 7 (28.57%) 3	0 / 8 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 7 (14.29%) 1	1 / 8 (12.50%) 5
Cystitis subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1
Fungal infection subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Influenza subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Liver abscess subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Paraspinal abscess subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	2 / 7 (28.57%) 2	4 / 8 (50.00%) 4
Hyperglycaemia			

subjects affected / exposed	0 / 14 (0.00%)	0 / 7 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Folate deficiency			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Hypokalaemia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 7 (14.29%)	0 / 8 (0.00%)
occurrences (all)	0	1	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 July 2013	The primary reason for Amendment 3 was to include the pembrolizumab 2 mg/Kg Q3W study arm and to remove the 10 mg/kg Q2W arm.
15 April 2014	The primary reason for Amendment 8 was to implement stratification by PD-L1 status as strong positive versus weak positive.
07 July 2015	The primary reason for Amendment 10 was to move OS and PFS from secondary to primary objectives.
11 December 2015	The primary reason for Amendment 12 was to include switch over of docetaxel treated participants to pembrolizumab 2 mg/Kg Q3W, as long as inclusion/exclusion criteria were met.
11 January 2018	The primary reason for Amendment 15 was to update treatment in the second and switch over pembrolizumab courses to a fixed dose of 200 mg Q3W.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported